Unknown

Dataset Information

0

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

ABSTRACT: We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

SUBMITTER: Lopez A 

PROVIDER: S-EPMC4588395 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-l  ...[more]

Similar Datasets

Unknown Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.
| S-EPMC8419764 | biostudies-literature
Unknown Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients.
| S-EPMC7694236 | biostudies-literature
Unknown Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
| S-EPMC5394964 | biostudies-literature
Unknown Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
| S-EPMC7894296 | biostudies-literature
Unknown Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
| S-EPMC7552812 | biostudies-literature
Unknown Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
| S-EPMC2394229 | biostudies-other
Unknown Outcome of Elderly Patients With Surgically Treated Brain Metastases.
| S-EPMC8350563 | biostudies-literature
Unknown Waldenstrom's macroglobulinemia front line treatment.
| S-EPMC8925655 | biostudies-literature
Unknown Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting
| S-EPMC11223993 | biostudies-literature
Unknown Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.
| S-EPMC6795854 | biostudies-literature